Navigation Links
Palatin Technologies, Inc. To Report Fiscal Year 2013 Second Quarter Results; Teleconference and Webcast to be held on February 14, 2013
Date:2/8/2013

CRANBURY, N.J., Feb. 8, 2013 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE-MKT: PTN) will announce its second quarter, fiscal year 2013 financial results on Thursday, February 14, 2013 before the open of the U.S. financial markets.

Palatin will also conduct a conference call and live audio webcast hosted by its executive management team on February 14, 2013, which will include discussion of the results of operations in greater detail and an update on corporate developments.

Schedule for the Financial Results Press Release, Conference Call / Webcast- 2Q Fiscal Year 2013 Financial Results Press Release

2/14/2013 at 7:30 a.m. ET- 2Q Fiscal Year 2013 Conference Call-Live

2/14/2013 at 11:00 a.m. ET  Domestic Dial-In Number

1-888-539-3678  International Dial-In Number

1-719-325-2329  Passcode

4795478- 2Q Fiscal Year 2013 Conference Call-Replay

2/14/2013-2/21/2013  Domestic Dial-In Number

1-888-203-1112  International Dial-In Number

1-719-457-0820  Passcode

4795478  Webcast Live and Replay Access

http://www.palatin.comThe webcast and replay can be accessed by logging on to the "Investor/Media Center-Webcasts" section of Palatin's website at http://www.palatin.com

About Palatin Technologies, Inc.
Palatin Technologies, Inc. is a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. Palatin's strategy is to develop products and then form marketing collaborations with industry leaders in order to maximize their commercial potential.


'/>"/>
SOURCE Palatin Technologies, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Palatin Technologies, Inc. to Present at 15th Annual BIO CEO & Investor Conference
2. Palatin Technologies, Inc. to Present at the 24th Annual Piper Jaffray Healthcare Conference
3. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2013 Results; Teleconference and Webcast to be held on November 14, 2012
4. Palatin Technologies, Inc. To Present At The Lazard Capital Markets 9th Annual Healthcare Conference
5. Palatin Technologies, Inc. To Report Fiscal Year 2013 First Quarter Results; Teleconference and Webcast to be held on November 14, 2012
6. Palatin Technologies Reports Positive Results for Phase 2B Bremelanotide Female Sexual Dysfunction Trial
7. Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2012 Results
8. Palatin Technologies Provides Update Regarding Its Obesity Research/Development Collaboration with AstraZeneca
9. Palatin Technologies, Inc. To Report Fiscal Year 2012 Fourth Quarter Results; Teleconference and Webcast to be held on September 11, 2012
10. Palatin Technologies, Inc. Announces Pricing of $35 Million Private Placement of Common Stock and Warrants
11. Palatin Technologies Announces Halting of Phase I Clinical Trial of Obesity Compound in AstraZeneca Research Collaboration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... ... a basic first aid supply for any work environment, but most personal eye wash can ... a dangerous substance enters both eyes? It’s one less decision, and likely quicker response time ... , “Whether its dirt and debris, or an acid or alkali, getting anything in your ...
(Date:10/11/2017)...  VMS BioMarketing, a leading provider of patient support solutions, ... Educator (CNE) network, which will launch this week. The VMS ... care professionals to enhance the patient care experience by delivering ... health care professionals to help women who have been diagnosed ... ...
(Date:10/11/2017)... Austin, TX (PRWEB) , ... October 11, 2017 ... ... in August compared the implantation and pregnancy rates in frozen and fresh ... the contribution of progesterone and maternal age to IVF success. , After comparing ...
(Date:10/10/2017)... (PRWEB) , ... October 10, ... ... development-stage cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) therapeutics, today confirmed ... targeted HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed in collaboration with ...
Breaking Biology Technology:
(Date:10/4/2017)... , Oct. 4, 2017  GCE Solutions, a global clinical ... data and document anonymization solution on October 4, 2017. Shadow is ... field to comply with policy 0070 of the European Medicines Agency ... data. ... GCE Solutions ...
(Date:7/20/2017)... Delta (NYSE: DAL ) customers now can use ... Reagan Washington National Airport (DCA). ... Delta launches biometrics to board aircraft at Reagan Washington ... Delta,s biometric boarding pass experience that ... integrated into the boarding process to allow eligible Delta SkyMiles Members who ...
(Date:6/14/2017)... IBM ) is introducing several innovative partner startups at ... between startups and global businesses, taking place in ... startups will showcase the solutions they have built with IBM ... France is one of the most ... increase in the number of startups created between 2012 and ...
Breaking Biology News(10 mins):